Ocugen shared the story of an OCU400 trial participant with retinitis pigmentosa, spotlighting the patient impact of its experimental gene therapy and its broad

BWB News TV • 2026-07-27 20:11 UTC • By Billy Odell Tucker-Robinson

Ocugen shared the story of an OCU400 trial participant with retinitis pigmentosa, spotlighting the patient impact of its experimental gene therapy and its broader push in rare inherited retinal disease research.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly